Findings from the Parker Institute for Cancer Immunotherapy (PICI) and its collaborative network of researchers, including from the University of Pennsylvania, presented at 2022 ASCO Annual Meeting and published in Nature Medicine New data from the PRINCE clinical trial, co-funded by PICI, Bristol Myers Squibb and the Cancer Research Institute in collaboration with Apexigen, could … [Read more…]

Insulet Presents Pivotal Extension Data for Preschool Children and Other Omnipod® 5 System Clinical Research at American Diabetes Association 82nd Scientific Sessions ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System … [Read more…]

Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval LOS ANGELES–(BUSINESS WIRE)–Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions to the closing of its pending business combination with Alvotech Holdings S.A. and Alvotech (“Topco”) (the “Business Combination”), including approval of the … [Read more…]

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not appropriately address the U.S. Food and Drug Administration’s questions about the benefit-risk profile of Reblozyl … [Read more…]

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”) announces that the TSX Venture Exchange has granted a second extension of up to 30 days for completion of the balance of the Company’s previously announced non-brokered private placement of … [Read more…]

— Largest Analysis Examining Use of CAR T-cell Therapy Across Race and Ethnicity — — Black or African American Patients Experienced Longer Time from Diagnosis to Infusion Compared to White Patients, Possibly Impacting Overall and Complete Response Rates; More Study Warranted — — Clinical Trials of Yescarta in the U.S. and Real-World Use from CIBMTR … [Read more…]

– Children’s Oncology Group (COG) to Present Data from Investigator-sponsored Study at 59th American Society of Clinical Oncology (ASCO) Annual Meeting – – Phase 3 Clinical Trial of ADCETRIS Combination Therapy Demonstrated a 59% Reduction in Risk of Disease Progression or Relapse, Second Malignancy or Death vs. Standard of Care – – Data Supported Seagen’s … [Read more…]

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–On April 8, 2022, Priority Health became aware of a missing box of medical claims and records. These files were lost in transit to a vendor located in Texas. FedEx has not been able to locate the box and the vendor has no record of receiving it. The information in the FedEx … [Read more…]

Dr. Klein to Discuss Trends and Innovations Shaping the Industry with Fellow Panelists from UCSF, Hill Physicians Medical Group, Kaiser, Anthem, Carbon Health, and Modern Health   GREENBRAE, Calif.–(BUSINESS WIRE)–MarinHealth today announced that CEO David Klein, MD, MBA, will be speaking at the San Francisco Business Times’ upcoming event on the Future of Healthcare, which … [Read more…]

Company’s multivariate blood-based test can serve as a quantitative and objective tool to evaluate an individual patient’s level of disease activity as well as overall disease activity of a clinic’s population MENLO PARK, Calif.–(BUSINESS WIRE)–Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis … [Read more…]